Search
-
Public Opinion on the COVID-19 pandemic
In an uncertain world, data matters. Ipsos experts share the latest research and analysis related to the coronavirus pandemic.
-
Decoding the patient journey with social insights
Social insights have become a critical component of understanding patients, HCPs, and caregivers – and a key input into developing products and services that meet their needs.
-
Myths and vaccines: building pharma reputation in the face of misinformation
The ongoing pandemic has placed the pharmaceutical industry in the spotlight like never before. Alongside the fight against COVID-19, effectively communicating with stakeholders is more important than ever.
-
[WEBINARS] Consumers, Citizens, Brands, Governments and the coronavirus crisis
As a result of the Covid-19 crisis, the world is changing even faster now than ever. For companies, government institutions and individuals, it is important now to not only focus on the short term, but also to make plans for the future. As we move from the “age of uncertainty” to the “time of coronavirus”, how will we adapt as consumers, citizens, and humans?
-
Leading pharmaceutical brands demonstrating leadership
As Covid-19 continues to disrupt traditional care norms, major pharma products have an unprecedented opportunity to define new market dynamics and demonstrate population health leadership.
-
The Ipsos Almanac 2019
Welcome to the Ipsos 2019 Almanac - a look at what our research has told us about the state of Britain in another year of Brexit and a general election.
-
How reputation and trust affect purchase decisions and marketing efficiency
How does reputation influence purchase decisions?
-
Global perspectives on sector reputations
Which industries are facing the greatest reputation challenges at the moment?
-
Who Will Win the Race to Treat NASH?
Non-alcoholic Steatohepatitis, or NASH, is a liver disease characterized by rising prevalence, low diagnosis and a lack of therapies approved for treatment. All of these factors combine to make NASH a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. Accordingly, the race is now on among several pharma companies to develop the first effective pharmacotherapy to treat NASH.